Entering text into the input field will update the search result below

Harpoon Therapeutics assumed with a Buy at Canaccord

Jul. 06, 2022 2:45 PM ETHARPBy: Pranav Ghumatkar, SA News Editor
  • Canaccord analyst William Maughan assumed coverage of Harpoon Therapeutics (HARP) with a Buy rating and $16 price target.
  • Bispecific T-cell engagers, like the ones Harpoon is developing, are "among the hottest therapeutic strategies in development for oncology," said Maughan, who adds that Harpoon has been "a

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.